Biocon Ltd. is set to seek regulatory approvals for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting key markets like Canada, where patents expire next year. Managing Director Siddharth Mittal sees Canada as a prime opportunity, aiming for potential approval in 2026.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SAtE7h3
via IFTTT
-
Acquista ********, Ossicodone, Ketamina, Ozempic (WhatsApp: +31616337954) I nostri prodotti hanno una purezza del 98-99%. E-mail di cont...
-
So I’m currently on a lean bulk on 2900 a day. And I wake up 6 am I have oats and protein powder or fruit then go gym around 9 am Then at ...
-
Kotak Alternate Asset Managers has announced a Rs 1,445 crore investment in the acquisition of Viatris' active pharmaceutical ingredient...
Search This Blog
Powered by Blogger.
Recent Posts
Unordered List
Theme Support
-
Text Widget
Design by FlexiThemes | Blogger Theme by Lasantha - PremiumBloggerTemplates.com | Best Gadgets | Distributed By Gooyaabi Templates
0 comments:
Post a Comment